blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP3181566

EP3181566 - IMIDAZOTRIAZINONE COMPOUNDS [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  08.06.2018
Database last updated on 11.09.2024
FormerRequest for examination was made
Status updated on  28.12.2017
FormerThe application has been published
Status updated on  19.05.2017
Most recent event   Tooltip08.06.2018Withdrawal of applicationpublished on 11.07.2018  [2018/28]
Applicant(s)For all designated states
Ironwood Pharmaceuticals, Inc.
301 Binney Street
Cambridge, MA 02142 / US
[2017/25]
Inventor(s)01 / RIPKA, Amy
1446 Main Street
Reading, MA 01867 / US
02 / SHAPIRO, Gideon
5507 NW 80th Avenue
Gainesville, FL 32653 / US
03 / CHESWORTH, Richard
584 Strawberry Hill Road
Concord, MA 01742 / US
04 / KOENIG, Gerhard
1662 Commonwealth Avenue
Newton, MA 02465 / US
 [2017/25]
Representative(s)HGF
4th Floor
Merchant Exchange
17-19 Whitworth Street West
Manchester M1 5WG / GB
[N/P]
Former [2017/25]HGF Limited
4th Floor
Merchant Exchange
17-19 Whitworth Street West
Manchester M1 5WG / GB
Application number, filing date16197573.520.09.2011
[2017/25]
Priority number, dateUS20100384694P20.09.2010         Original published format: US 384694 P
[2017/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3181566
Date:21.06.2017
Language:EN
[2017/25]
Search report(s)(Supplementary) European search report - dispatched on:EP13.03.2017
ClassificationIPC:C07D487/04, A61P25/00, A61K31/53
[2017/25]
CPC:
C07D487/04 (EP,US); A61P21/00 (EP); A61P25/00 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP);
A61P25/20 (EP); A61P25/22 (EP); A61P25/28 (EP);
A61P27/06 (EP); A61P31/18 (EP); A61P43/00 (EP);
C07D519/00 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/04]
Former [2017/25]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:IMIDAZOTRIAZINONVERBINDUNGEN[2017/25]
English:IMIDAZOTRIAZINONE COMPOUNDS[2017/25]
French:COMPOSES IMIDAZOTRIAZINONES[2017/25]
Examination procedure07.11.2016Date on which the examining division has become responsible
19.12.2017Amendment by applicant (claims and/or description)
19.12.2017Examination requested  [2018/04]
04.06.2018Application withdrawn by applicant  [2018/28]
Parent application(s)   TooltipEP11761793.6  / EP2619208
Fees paidRenewal fee
07.11.2016Renewal fee patent year 03
07.11.2016Renewal fee patent year 04
07.11.2016Renewal fee patent year 05
07.11.2016Renewal fee patent year 06
27.09.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO03037432  (PFIZER PROD INC [US], et al) [A] 1-11 * claims 2, 10 *;
 [A]WO2004096811  (PFIZER PROD INC [US], et al) [A] 1-11 * claims 1, 8 *;
 [IA]WO2008139293  (PFIZER [US], et al) [I] 1,3-5,7-11 * claims 1, 10-12 * * example - * [A] 2,6;
 [A]  - WERMUTH C G, "MOLECULAR VARIATIONS BASED ON ISOSTERIC REPLACEMENTS", PRACTICE OF MEDICINAL CHEMISTRY, XX, XX, (1996), pages 203 - 237, XP002190259 [A] 1-11 * part II.D. *
by applicantEP0039051
 WO2004078163
    - FISHER ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, (1998), vol. 273, no. 25, pages 15559 - 15564
    - VAN DER STAAY ET AL., NEUROPHARMACOLOGY, (2008), vol. 55, no. 5, pages 908 - 918
    - HUTTSON ET AL., NEUROPHARMACOLOGY, (2011), vol. 61, no. 4, pages 665 - 676
    - Handbook of Pharmaceutical Salts, Properties, Selection and Use, WILEY-VCH
    - BUNDGAARD, J. MED. CHEM., (1989), page 2503
    - LAZORTHES ET AL., ADVANCES IN DRUG DELIVERY SYSTEMS AND APPLICATIONS IN NEUROSURGERY, pages 143 - 192
    - OMAYA ET AL., CANCER DRUG DELIVERY, vol. 1, pages 169 - 179
    - MINTO, J. PHARMACOL. EXP. THER., (1997), vol. 281, pages 93 - 102
    - Remington's Pharmaceutical Sciences, MAACK PUBLISHING CO
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.